Although no one claimed a breakthrough antimicrobial, several new compounds appear to be promising antibacterial agents while the lone featured antiviral compound in this segment marks the first specific agent for treating hepatitis C viral (HCV) infections, according to the medley of presentations during the "Poster Summary Session," convened as part of the 2006 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in September.
HCV-796 is a selective, nonnucleoside inhibitor of HCV, which is a major cause of chronic hepatitis that leads to cirrhosis and is a risk factor for liver cancer, according to Eugene Amparo of ViroPharma Inc. in Exton, Pa., speaking for his collaborators there and at Wyeth Research Laboratories in Collegeville, Pa., and Pearl River, N.Y. Although such infections are being treated with interferon alone or combined with ribiviron, such treatment courses "can be difficult," he says. The new compound, an extensively modified benzofuran, is "very potent" against HCV when tested in mammalian cells; it is expected to advance to phase II clinical trials.
Among the antibacterials that were showcased at ICAAC, the ceragenins belong to an intriguing class of membrane-active mimics of antimicrobial peptides. These compounds are broad in spectrum, rapid in their killing action, and very potent, according to Paul Savage of Brigham Young University in Provo, Utah, who is collaborating with a team at Ceragenix Pharmaceuticals in Denver, Colo. The peptide mimetics are "easy to make on a large scale," he points out.
One derivative that is particularly active against gram-positive pathogens is being developed as a topically applied product for controlling eye infections. When tested in rabbits, the compound is "well tolerated," Savage says. Meanwhile, other ceragenins that are active against bacterial biofilms are being incorporated into polymer carriers that release the agents slowly, he adds. These formulations may be used in catheters or similar medical devices to prevent them from becoming contaminated with biofilms.
Some of these new candidate antibiotics have unusually narrow action spectrums. For example, AR-709, a diamopyrimidine that is being developed by a team at Arpida in Muenchenstein, Switzerland, is active mainly against Streptococcus pneumoniae. This candidate drug, which came from a program seeking agents to overcome drug-resistant streptococci, is an inhibitor of dihydrofolate reductase, in the same vein as trimethoprim, according to Stephen Hawser of Arpida. However, AR-709 offers several advantages over trimethoprim, including better antimicrobial activity, bactericidal activity in vitro, and a "low propensity" to develop resistance, he says.
Similarly, Affinium Pharmaceuticals of Toronto, Ontario, Canada, is developing API-1252, which in this case is active almost exclusively against Staphylococcus, according to Nachum Kaplan. The candidate drug targets bacterial fatty acid synthesis, is "exceptionally active" against methicillin-resistant Staphylococcus aureus (MRSA), and is effective when administered orally or intravenously in mice. Its narrow spectrum means there is "no off-target killing," including in the gastrointestinal tract of the treated host, he notes. The company expects API-1252 to enter human trials in 2007.
BAL19403 also falls within this series of narrowly acting antibacterials. This macrolide antibiotic, described by Jurg Dreier of Basilea Pharmaceutica in Basel, Switzerland, is especially potent against Propionibacteria acnes. The compound is not only antibacterial, but also has anti-inflammatory properties and a "wide safety margin" with little systemic absorption, making it a strong candidate for becoming a topical treatment for acne, he says.
Several of the other newer antibacterial compounds that were in the spotlight at ICAAC are from familiar classes of antibiotics, or are intended to augment the activity of some of those antibiotics. Most of these antibacterial agents have broad-spectrum activities. For example, John Buynak of Southern Methodist University in Dallas, Tex., and his collaborators at JMI Laboratories in North Liberty, Iowa, and at several institutions in Cleveland, Ohio, are developing a series of ␤-lactamase inhibitors to improve the activities of the penicillin and cephalosporin antibiotics. If successful, one of these inhibitors, which lack antibacterial activity on their own, would be used with an established antibiotic in this class, he notes.
One such inhibitor, a penicillin-derived sulfone designated LN-1-255, closely resembles the substrate of serine ␤-lactamases and probably acts by acylating that enzyme, making it difficult for microbes to develop resistance, Buynak says. Although this inhibitor "won't be the ultimate drug" because of its effects on catechols, it is a promising lead on the basis of its synergy with several ␤-lactam antibiotics, including third-generation cephalosporins, making them active again in vitro against gram-negative pathogens that were otherwise resistant to this antibiotic.
PZ-601 is an injectable carbapenem that could prove useful against multiply drug-resistant gram-positive and some gram-negative pathogens, according to Clarence Young of Protez Pharmaceuticals in Malvern, Pa. Although the compound is bactericidal against MRSA strains, it is not active against Pseudomonas unless used in conjunction with antibiotics from another class, such as aminoglycosides, he says.
Meanwhile, DC-159a, an 8-methoxy derivative of the fluoroquinolone antibiotics, is orally available and shows broad-spectrum activity against both gram-positive and gram-negative pathogens, including "contemporary" isolates that are resistant to a variety of antibiotics, according to Kazuki Hoshino of Daiichi Pharmaceutical in Tokyo, Japan. Moreover, this compound appears not to promote selection for resistant mutants when tested in vitro, and its safety and pharmacodynamic properties make it "acceptable for clinical development," he says. It is also active against Mycobacterium tuberculosis, including isolates with multiple drug resistance.
Hygromycin A, an inhibitor of protein synthesis that was identified more than 60 years ago, was the starting point for making more highly potent derivatives that work mainly against gram-positive pathogens, including MRSA, says Gregory Stone of Pfizer in Groton, Conn. Several of those derivatives have activity profiles that are similar to linezolid, an oxazolidinone antibiotic that Pfizer markets as Zyvox.
Mahesh Patel and his collaborators at the Wockhardt Research Centre in Aurangabad, India, are working on oxazolidinone derivatives. Their strategy is to substitute for oxygen in the morpholine ring of the molecule to improve its stability, he says. Several of their derivatives have "good oral bioavailability," "longer lifetimes," and "better bone marrow safety profiles" than linezolid. The possibility that this phenomenon could prove more general for pathogens that infect humans "could lead to the development of vaccines or treatments for many bacterially caused diseases," Kronenberg says. Earlier hints about the extended reach of NKT cells came from analysis of two seemingly innocuous glycolipids, one isolated from a marine sponge and the other from the ubiquitous environmental bacterium Sphingomonas. However, neither the marine sponge nor Sphingomonas, which inhabits soil, water, and plants, is a hazard to human health. Thus, he wondered, "Why would the immune system care about Sphingomonas or a sponge?" That question sent him and his collaborators searching for other microbial sources of unusual glycolipids.
Another group of researchers at the National Institutes of Health in Bethesda, Md., independently identified a glycolipid-specifically, a 1,2-diacyl-3-O-␣-galactosyl-sn-glycerol-from cells of B. burgdorferi. Speculating that NKT cells might react to this unusual glycolipid, Kronenberg and his collaborators
Extremely Small Microbes
Carsonella ruddii, a symbiont of psyllid insects, carries the smallest bacterial genome yet characterized-a circular chromosome of 159,662 base pairs encoding 182 genes, according to Nancy Moran of the University of Arizona in Tucson, and her collaborators there and at several institutions in Japan. The genome has a very high coding density of 97%, includes many overlapping genes, but does not encode numerous genes that ordinarily are considered essential for life, suggesting that Carsonella is organelle-like, the researchers report in the 13 October Science. Buchnera aphidicola BCc, a symbiont of an aphid, also has a small genome, albeit containing 422,434 base pairs, that could still be shrinking, perhaps to make way for another symbiont to replace it, according to Ampara Latoree from of the Universitat de Valencia in Valencia, Spain, and his collaborators from there and elsewhere, whose findings appear in the same issue of Science.
determined that it accounts for 12% of the total lipids of B. burgdorferi.
Further, the purified diacylglycerol triggers the specific release of interleukin-2 from NKT cells and also directly stimulates T cell receptors on such cells, but not by indirect means through Toll-like receptors on antigen-presenting cells. In addition, NKT cells are activated in mice infected with B. burgdorferi via tick bites.
An ␣ linkage between the sugar and lipid components of this glycolipid proves crucial for its potent NKT-stimulating activity, according to Kronenberg. The glycolipids from the marine sponge and Sphingomonas contain a similar ␣ bond, giving all three of the glycolipids a particular stereochemistry. "The ␣ linkage really makes a difference and tilts the sugar in a different direction," he says. Other glycolipids, including those abundant in mammals, contain ␤ linkages between sugars and lipids, but those molecules "do not work as antigens for NKT cells," Kronenberg says. He speculates that the ␣ linkage might be involved in helping glycolipid antigens fit into hydrophobic grooves along target cells.
In the 1990s, researchers at Kirin Pharmaceuticals in Japan isolated the glycolipid from marine sponges that is now being evaluated for antitumor activity in clinical trials. Kronenberg and his collaborators identified the Sphingomonas glycolipid, which they described in Nature on March 24, 2005. Both the marine sponge and Sphingomonas glycolipids are ␣-galactosylceramides.
Kronenberg's discovery "is the first example of a glycolipid antigen from an important human pathogen, and it gives a fundamentally new perspective of antigens recognized by T cells," says Branch Moody, a rheumatologist and cellular immunologist at Harvard University in Boston, Mass. Because glycolipids constitute a significant percentage of microbial cell walls, it raises the possibility that other microbial glycolipids contain the unusual ␣ linkage, according to Moody. Moreover, such unconventional antigens for T cells could lead to the development of better vaccines or diagnostic tests.
Carol Potera
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Targeted Antimicrobial Peptides Could Help Stamp Out Tooth Decay
Although Streptococcus mutans shares the mouth with perhaps 700 other microbial species, selectively targeted antimicrobial peptides (STAMPs) might provide a "smart bomb" approach to sparing commensals while curbing tooth decay, according to Randal Eckert, Wenyuan Shi of the University of California, Los Angeles, and their collaborators. "This may convert dentistry from a surgical model to a medical model-from drilling and filling to treatment and prevention," Shi says. Applied to other anatomic sites, this same strategy also might improve matters for other diseases where antibiotic treatments can upset the local microbial ecology. Details of this research appear in the November issue of Antimicrobial . Like brushing, conventional antibiotic therapy indiscriminately disrupts a broad spectrum of microbes of the mouth, upsetting the local ecology and opening this niche for more intensive recolonization by S. mutans. An-
Optimism, Puzzlement over Influenza Behavior, Flu Vaccine Prospects
Efforts to probe the genetic history of the influenza virus continue as investigators prepare for an anticipated pandemic. Recent noteworthy developments include:
• The view that influenza viruses change as part of "a rapid, positive selection-driven process" needs to be reexamined, according to David Lipman and his collaborators from the National Library of Medicine National Center for Biotechnology Information Biology in Bethesda, Md. For instance, the hemagglutinin (HA) gene often is in apparent "stasis," suggesting that many cocirculating strains are equally fit. STAMPs combine a highly selective targeting domain with a wider-spectrum antimicrobial domain. In this case, Shi and his collaborators used part of a pheromone-like molecule from S. mutans to serve as the targeting domain. It was combined with a 16-amino-acid sequence from the wide-spectrum antimicrobial peptide novispirin G10. The resulting hybrid molecule proved highly effective when tested against planktonic S. mutans cells or mixed-species biofilms from human saliva. Indeed, it selectively kills S. mutans cells in mixed-species biofilms.
Synthesizing STAMPs is simple compared to other potentially targeted antimicrobials such as aminoglycoside antibiotics that are linked to antibodies that specifically target S. mutans. For these or similarly targeted antibiotics, "the chemical synthesis is pretty nasty," says J. William Costerton of the University of Southern California in Los Angeles. But when all the building blocks are amino acids, as with STAMPs, they can be strung together easily.
Costerton predicts that STAMPs could have an important impact on infections for which antibiotics "are the most compromised," including other diseases of the mouth such as periodontitis, middle ear infections, and prostatitis. STAMPs also might prove useful for treating infections by various pathogens found in the gastrointestinal (GI) tract, including Clostridium difficile, Helicobacter pylori, and virulent forms of Escherichia coli.
Other environments for such targeted approaches include the pathogenic culprits within mixed microbial communities that inhabit exposed mucous membranes such as the lungs, nose, and vagina. "We are actively pursuing medical applications," Shi says.
Costerton says that pathogens treated in this way are unlikely to develop resistance to STAMPs because they do not target one particular piece of the cellular machinery of the pathogen, where a single mutation could impart resistance. Instead, STAMPs act more generally on membranes, "messing them up," he says.
Of course, a single type of STAMP will not suffice if microbial species other than S. mutans are helping to cause dental caries. "Then we'd need another two or three peptides," Costerton says. Even so, he predicts, "The basic thrust of caries will be blunted by [STAMPs] . Even with fluoridation, there are still people who lose their teeth at an early age. I'm virtually certain mutans is the big one in these cases."
The idea for STAMPs emerged from a light-hearted discussion between Shi and Max Anderson, who then worked in the insurance industry as a vice president of the Delta Dental Plan. "Max took it seriously and convinced his board to support this technology, which is the first sponsored wet-lab research project ever by the Delta Dental company," Shi says. To control the New Zealand meningitis outbreak that persisted during the 1990s, Rappouli and his collaborators took what he calls "an oldfashioned approach" to developing a vaccine. Its main ingredient consists of outer membrane vesicles derived from killed bacterial cells. After this experimental vaccine proved safe and effective in clinical trials several years ago, it was administered widely to infants, children, and adolescents throughout the country, he says.
David Holzman
Public health officials now consider the epidemic to be under control in New Zealand. However, a similar epidemic continues in the northwest of France, where officials are beginning to inoculate children with a vaccine specifically designed for the regional outbreak. This otherwise conventional vaccine is being produced in Norway.
The annual incidence of meningococcal disease varies from 0.5 to 10 per 100,000 persons. Currently, serogroup B N. meningitidis disease is responsible for 32% of all meningococcal disease in the United States and from 45 to 80% of the cases in Europe. However, there is no broadly active vaccine to prevent such infections, and the vaccine that was used successfully in New Zealand is considered far too specific for use elsewhere, according to Rappouli.
Other efforts to develop a general purpose vaccine directed against MenB that date to the 1960s proved unsuccessful, Rappouli continues. However, those early conventional efforts ran into formidable obstacles. For one, serogroup B capsular polysaccharides contain sialyic acid, and antibodies raised to this antigen would likely cross-react with human tissues, ruling out polysaccharide-and conjugate-based vaccines that work so well in protecting children against other pathogens such as Haemophilus influenzae. For another, some surfaceexposed proteins of N. meningitidis are too variable to serve as antigens for making a vaccine.
Those earlier efforts came before bacterial genome sequencing came into vogue. Analysis of sequencing data describing the genome of MenB led Rappouli and his collaborators first to a set of 350 candidate antigenic proteins that that are surface exposed, conserved across strains, and induce a bactericidal antibody response. From that set, they eventually focused on five MenB minor proteins that had not been identified before, he says. "There is nothing striking about these proteins, which are novel and of unknown function."
However, when those five proteins are formulated with a "classical" adjuvant, they prove to be the basic ingredients of an effective and-on the basis of clinical trials-safe candidate vaccine for preventing MenB infections, he continues. Importantly, this vaccine elicits production of antibodies whose presence he calls "predictive of efficacy" because they can form complexes with complement factors that circulate within the human host that are bactericidal for MenB. If circumstances deteriorate at particular facilities, CDC suggests that patients at high risk for carrying drug-resistant bacteria be screened to ensure that "correct precautions are being used."
Mello of the University of Massachusetts Medical School in Worcester, recognize fundamental research involving nucleic acids. In Kornberg's case, the yeast Saccharomyces cerevisiae proved the eukaryote of choice. Fire and Mello's breakthroughs in understanding RNA interference depended on another eukaryote, Caenorhabditis elegans-a worm that likely deserves honorary microbial status because of its simplicity, versatility, and beloved status among basic researchers.
Kornberg's focus has been on transcription. Unlike bacteria, eukaryotes such as yeast contain three different forms of RNA polymerase, and each contains multiple subunits. Moreover, unlike bacterial RNA polymerases, these eukaryotic enzymes display no capacity for selective transcription of purified DNA and are not equipped with sigma factors, which are critical for modulating transcription among bacteria. Although genes in eukaryotes have promoters, they are more "extended" than those associated with bacterial genes.
Kornberg worked indirectly on transcription while doing structural studies on chromatin at the Medical Research Council in Cambridge, U.K., during the 1970s. Later, at Stanford, he focused more directly on transcriptional regulation, purifying RNA polymerase II from yeast and identifying a series of transcription factors. However, the failure of these components to respond to gene-specific activator proteins led him and his collaborators to identify a complex consisting of about 20 proteins that they called "mediator." Its role is to transfer signals from DNA-binding, gene-specific transcription factors to RNA polymerase II and the general transcription factors.
The next phase of Kornberg's research entailed developing detailed, three-dimensional images of how these complexes look. His approach involved both electron microscopy and X-ray crystallography, including a method for producing twodimensional protein crystals on lipid surfaces. These efforts led in 2001 to a description of the yeast RNA polymerase at 2.8 Å resolution along with an elongating complex consisting of RNA polymerase, template DNA, and product RNA.
KornbergЈs studies of eukaryotic transcription thus helped to provide a deep molecular understanding of promoter recognition, the mechanism of transcription initiation, how the DNA-RNA hybrid is translocated after the addition of a nucleotide, how the newly synthesized RNA strand is separated from the DNA template, and of the structural basis for accurate selection of an incoming ribonucleotide that is complementary to the DNA template.
Kornberg Moreover, the FDA should assume the key role of gathering and analyzing data on the risks and benefits of drugs after their approval when safety problems may become evident as products become more widely used, according to the report, which is available at http: //national-academies.org. cloning or also due to viral infections-sometimes inhibit, or "silence," expression of homologous sequences. In 1998, they determined that double-stranded RNA led to efficient losses of target messenger RNA molecules in C. elegans, and noted that these same biochemical steps might explain gene silencing in plants. Within a year, RNAi was documented in many other organisms besides worms and plants, including fruit flies, trypanosomes, planaria, hydra, and zebrafish.
RNAi amounts to a simple defense mechanism against viral attacks, one that operates in plants, worms, flies, and many other organisms but perhaps not effectively or at all in vertebrates. Nonetheless, the discovery of this special mechanism for suppressing gene expression adds a whole new chapter to our knowledge of gene control-specifically, how infection by RNA viruses or expression of foreign elements in the genome can be suppressed. RNAi not only provides a useful means for studying gene expression but may also prove useful in medicine as a means for controlling expression of errant genes.
Jeffrey L. Fox
Teaching an Old Worm New Tricks. . .through Quorum Sensing
The roundworm Caenorhabditis elegans is attracted to particular quorum-sensing autoinducers made by gram-negative bacteria. More impressively, the worm apparently learns to avoid such autoinducers after being exposed to autoinducer-producing pathogens, according to Kendra P. Rumbaugh of the Texas Tech University Health Sciences Center in Lubbock and her collaborators. They reported their findings in the July issue of Applied and Environmental .
The report "confirms research published last year showing that C. elegans can learn to avoid pathogenic bacteria," says Fred Ausubel of Harvard Medical School in Boston, Mass., who calls the Texas Tech study "very solid."
The Texas Tech research extends that earlier work by examining what specific compounds C. elegans might be sensing while it acquires this lifepreserving distaste for pathogens, according to Rumbaugh. She and her collaborators exposed C. elegans to several quorum-sensing autoinducers belonging to the series of acylated homoserine lactone autoinducers (AHSL) that some kinds of gramnegative bacteria produce. When the researchers placed the autoinducers on a "chemotaxis" agar plate, the worms were attracted to all autoinducers tested and preferentially moved towards them.
The investigators then exposed C. elegans to the pathogen Pseudomonas aeruginosa, which produces an AHSL autoinducer called Pseudomonas autoinducer-1 (PAI-1). After a short exposure to PAI-1, instead of being attracted, the roundworms were now repelled by it, Rumbaugh says. "C. elegans may use the ability to sense autoinducers to find food sources in nature," she continues. "It may also be able to learn to distinguish the good food sources from the pathogenic by differentiating between autoinducers." She compares the conditioning shown in C. elegans to mammalian taste aversions that lead animals, including humans, to avoid bad-tasting foods that could make them sick.
"Numerous bacterial functions have been attributed to AHSL signaling, including virulence factor production in Pseudomonas aeruginosa," Rumbaugh and her colleagues note. "Several recent studies suggest the AHSLs not only function in bacterial signaling but also are capable of modulating several signaling pathways in eukaryotic cells. . ." "Autoinducers are very similar functionally and structurally to mammalian hormones," Rumbaugh says. "We postulate that organisms from the different kingdoms of nature have acquired mechanisms to sense and respond to each other's signaling molecules, and we have named this process interkingdom signaling. We further propose that autoinducers are excellent candidates for mediating this interkingdom communication." "This type of behavior [the Texas Tech researchers show in C. elegans] is likely to be shared by other nematode species," says Jonathan Ewbank of the University of the Mediterranean in Marseille, France. Nematodes cause an estimated $80 billion annually in crop damage, and are human and animal pathogens as well. This line of research "could open up new avenues of nematode control," he says The Texas Tech research "also suggests that detection of autoinducers is evolutionarily ancient, and opens the possibility that the molecular mechanisms of recognition will be conserved from invertebrates to vertebrates."
David Holzman

